Cargando…

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients

BACKGROUND: PD-L1 receptor expression in breast cancer tissue can be assessed with different anti-human PD-L1 monoclonal antibodies. The performance of three specific monoclonal antibodies in a head-to-head comparison is unknown. In addition, a potential correlation of PD-L1 expression and clinico-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Gilda, Guhl, Margit Maria, Solomayer, Erich-Franz, Wagenpfeil, Gudrun, Hammadeh, Mohammed Eid, Juhasz-Boess, Ingolf, Endrikat, Jan, Kasoha, Mariz, Bohle, Rainer Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519646/
https://www.ncbi.nlm.nih.gov/pubmed/35377046
http://dx.doi.org/10.1007/s00404-022-06529-w
_version_ 1784799446406529024
author Schmidt, Gilda
Guhl, Margit Maria
Solomayer, Erich-Franz
Wagenpfeil, Gudrun
Hammadeh, Mohammed Eid
Juhasz-Boess, Ingolf
Endrikat, Jan
Kasoha, Mariz
Bohle, Rainer Maria
author_facet Schmidt, Gilda
Guhl, Margit Maria
Solomayer, Erich-Franz
Wagenpfeil, Gudrun
Hammadeh, Mohammed Eid
Juhasz-Boess, Ingolf
Endrikat, Jan
Kasoha, Mariz
Bohle, Rainer Maria
author_sort Schmidt, Gilda
collection PubMed
description BACKGROUND: PD-L1 receptor expression in breast cancer tissue can be assessed with different anti-human PD-L1 monoclonal antibodies. The performance of three specific monoclonal antibodies in a head-to-head comparison is unknown. In addition, a potential correlation of PD-L1 expression and clinico-pathological parameters has not been investigated. METHODS: This was a retrospective study on tissue samples of patients with histologically confirmed triple negative breast cancer (TNBC). PD-L1 receptors were immune histochemically stained with three anti-human PD-L1 monoclonal antibodies: 22C3 and 28-8 for staining of tumor cell membranes (TC) and cytoplasm (Cyt), SP142 for immune cell staining (IC). Three different tissue samples of each patient were evaluated separately by two observers in a blinded fashion. The percentage of PD-L1 positive tumor cells in relation to the total number of tumor cells was determined. For antibodies 22C3 and 28-8 PD-L1 staining of 0 to < 1% of tumor cells was rated "negative", 1–50% was rated "positive" and > 50% was rated "strong positive". Cyt staining was defined as “negative” when no signal was observed and as “positive”, when any positive signal was observed. For IC staining with SP142 all samples with PD-L1 expression ≥ 1% were rated as “positive”. Finally, the relationship between PD-L1 expression and clinico-pathological parameters was analyzed. RESULTS: Tissue samples from 59 of 60 enrolled patients could be analyzed. Mean age was 55 years. Both the monoclonal antibodies 22C3 and 28-8 had similar properties, and were positive for both TC in 13 patients (22%) and for Cyt staining in 24 patients (40.7%). IC staining with antibody SP142 was positive in 24 patients (40.7%), who were also positive for Cyt staining. The differences between TC and Cyt staining and TC and IC staining were significant (p = 0.001). Cases with positive TC staining showed higher Ki67 expression compared to those with negative staining, 40 vs 30%, respectively (p = 0.05). None of the other clinico-pathological parameters showed any correlation with PDL1 expression. CONCLUSIONS: Antibodies 22C3 and 28-8 can be used interchangeably for PD-L1 determination in tumor cells of TNBC patients. Results for Cyt staining with 22C3 or 28-8 and IC staining with SP142 were identical. In our study PD-L1 expression correlates with Ki67 expression but not with OS or DFS.
format Online
Article
Text
id pubmed-9519646
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-95196462022-09-30 Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients Schmidt, Gilda Guhl, Margit Maria Solomayer, Erich-Franz Wagenpfeil, Gudrun Hammadeh, Mohammed Eid Juhasz-Boess, Ingolf Endrikat, Jan Kasoha, Mariz Bohle, Rainer Maria Arch Gynecol Obstet Gynecologic Oncology BACKGROUND: PD-L1 receptor expression in breast cancer tissue can be assessed with different anti-human PD-L1 monoclonal antibodies. The performance of three specific monoclonal antibodies in a head-to-head comparison is unknown. In addition, a potential correlation of PD-L1 expression and clinico-pathological parameters has not been investigated. METHODS: This was a retrospective study on tissue samples of patients with histologically confirmed triple negative breast cancer (TNBC). PD-L1 receptors were immune histochemically stained with three anti-human PD-L1 monoclonal antibodies: 22C3 and 28-8 for staining of tumor cell membranes (TC) and cytoplasm (Cyt), SP142 for immune cell staining (IC). Three different tissue samples of each patient were evaluated separately by two observers in a blinded fashion. The percentage of PD-L1 positive tumor cells in relation to the total number of tumor cells was determined. For antibodies 22C3 and 28-8 PD-L1 staining of 0 to < 1% of tumor cells was rated "negative", 1–50% was rated "positive" and > 50% was rated "strong positive". Cyt staining was defined as “negative” when no signal was observed and as “positive”, when any positive signal was observed. For IC staining with SP142 all samples with PD-L1 expression ≥ 1% were rated as “positive”. Finally, the relationship between PD-L1 expression and clinico-pathological parameters was analyzed. RESULTS: Tissue samples from 59 of 60 enrolled patients could be analyzed. Mean age was 55 years. Both the monoclonal antibodies 22C3 and 28-8 had similar properties, and were positive for both TC in 13 patients (22%) and for Cyt staining in 24 patients (40.7%). IC staining with antibody SP142 was positive in 24 patients (40.7%), who were also positive for Cyt staining. The differences between TC and Cyt staining and TC and IC staining were significant (p = 0.001). Cases with positive TC staining showed higher Ki67 expression compared to those with negative staining, 40 vs 30%, respectively (p = 0.05). None of the other clinico-pathological parameters showed any correlation with PDL1 expression. CONCLUSIONS: Antibodies 22C3 and 28-8 can be used interchangeably for PD-L1 determination in tumor cells of TNBC patients. Results for Cyt staining with 22C3 or 28-8 and IC staining with SP142 were identical. In our study PD-L1 expression correlates with Ki67 expression but not with OS or DFS. Springer Berlin Heidelberg 2022-04-04 2022 /pmc/articles/PMC9519646/ /pubmed/35377046 http://dx.doi.org/10.1007/s00404-022-06529-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Gynecologic Oncology
Schmidt, Gilda
Guhl, Margit Maria
Solomayer, Erich-Franz
Wagenpfeil, Gudrun
Hammadeh, Mohammed Eid
Juhasz-Boess, Ingolf
Endrikat, Jan
Kasoha, Mariz
Bohle, Rainer Maria
Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
title Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
title_full Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
title_fullStr Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
title_full_unstemmed Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
title_short Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
title_sort immunohistochemical assessment of pd-l1 expression using three different monoclonal antibodies in triple negative breast cancer patients
topic Gynecologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519646/
https://www.ncbi.nlm.nih.gov/pubmed/35377046
http://dx.doi.org/10.1007/s00404-022-06529-w
work_keys_str_mv AT schmidtgilda immunohistochemicalassessmentofpdl1expressionusingthreedifferentmonoclonalantibodiesintriplenegativebreastcancerpatients
AT guhlmargitmaria immunohistochemicalassessmentofpdl1expressionusingthreedifferentmonoclonalantibodiesintriplenegativebreastcancerpatients
AT solomayererichfranz immunohistochemicalassessmentofpdl1expressionusingthreedifferentmonoclonalantibodiesintriplenegativebreastcancerpatients
AT wagenpfeilgudrun immunohistochemicalassessmentofpdl1expressionusingthreedifferentmonoclonalantibodiesintriplenegativebreastcancerpatients
AT hammadehmohammedeid immunohistochemicalassessmentofpdl1expressionusingthreedifferentmonoclonalantibodiesintriplenegativebreastcancerpatients
AT juhaszboessingolf immunohistochemicalassessmentofpdl1expressionusingthreedifferentmonoclonalantibodiesintriplenegativebreastcancerpatients
AT endrikatjan immunohistochemicalassessmentofpdl1expressionusingthreedifferentmonoclonalantibodiesintriplenegativebreastcancerpatients
AT kasohamariz immunohistochemicalassessmentofpdl1expressionusingthreedifferentmonoclonalantibodiesintriplenegativebreastcancerpatients
AT bohlerainermaria immunohistochemicalassessmentofpdl1expressionusingthreedifferentmonoclonalantibodiesintriplenegativebreastcancerpatients